FPGEE Blueprint

The FPGEE Competency Statements serve as a blueprint of the topics covered on the examination. They offer important information about the knowledge, judgment, and skills you are expected to demonstrate while taking the FPGEE. A strong understanding of the Competency Statements will aid you in your preparation to take the examination.

Competency Statements

Area 1 - Basic Biomedical Sciences (16%)

1A Physiology

  • 1A01 structure and function of major body systems; as it applies to integumentary, muscular skeletal, cardiovascular, lymphatic, respiratory, digestive, nervous, endocrine, urinary, reproductive, and body fluids and electrolytes, cells in tissue

1B Biochemistry

  • 1B01 chemistry of biomacromolecules (proteins, lipids, carbohydrates, and DNA)
  • 1B02 nucleic acid biosynthesis and metabolism
  • 1B03 enzymology and coenzymes and kinetics
  • 1B04 metabolic pathways to energy utilization

1C Microbiology

  • 1C01 general principles of microbial concepts
  • 1C02 principles of infectious diseases
  • 1C03 host-parasite relationships
  • 1C04 pathogenic microorganisms of man
  • 1C05 inflammatory responses to infectious agents

1D Molecular Cell Biology/Genetics

  • 1D01 gene expression
  • 1D02 carrier proteins/membrane transport
  • 1D03 mechanics of cell division
  • 1D04 ion channels and receptor physiology
  • 1D05 chromosomes and DNA
  • 1D06 gene transcription and translation processes
  • 1D07 recombinant DNA technology

1E Immunology

  • 1E01 human immunity and immune responses
  • 1E02 principles of antigen-antibody relationships
  • 1E03 antibody synthesis, development, function, and immunopathology

Area 2 – Pharmaceutical Sciences (30%)

2A Medicinal Chemistry

  • 2A01 physiochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)
  • 2A02 chemical basis for drug action
  • 2A03 fundamental pharmacophores for drugs used to treat diseases
  • 2A04 structure activity relationships in relation to drug-target interactions
  • 2A05 chemical pathways of drug metabolism
  • 2A06 applicability to making drug therapy decisions

2B Pharmacology and Toxicology

  • 2B01 mechanisms of action of drugs of various categories
  • 2B02 pharmacodynamics of drug action and absorption, distribution, metabolism, and elimination
  • 2B03 adverse effects and side-effects of drugs
  • 2B04 drug-target interactions
  • 2B05 drug discovery and development
  • 2B06 mechanism of toxicity and toxicokinetics
  • 2B07 acute and chronic toxic effect of xenobiotics, including drug and chemical overdose and toxic signs of drugs of abuse
  • 2B08 interpretation of drug screens
  • 2B09 principles of antidotes and alternative approaches to toxic exposures
  • 2B10 functions of poison control centers
  • 2B11 bioterrorism and disaster preparedness and management

2C Pharmacognosy and Alternative and Complementary Treatments

  • 2C01 concepts of crude drugs, semi-purified, and purified natural products
  • 2C02 evaluation of alternative and complementary medicine purity, bioavailability, safety, and efficacy
  • 2C03 classes of pharmacologically active natural products
  • 2C04 Science of dietary supplements (vitamins, minerals, and herbals)
  • 2C05 Dietary Health Supplement and Education Act and Impact on regulation of dietary supplements and herbal products

2D Pharmaceutics

  • 2D01 physiochemical principles of dosage forms
  • 2D02 principles of drug delivery via dosage forms (eg, liquid, solid, semi-solid, controlled release, patches, and implants)
  • 2D03 principles of dosage form stability and drug degradation in dosage forms
  • 2D04 materials and methods used in preparation and use of drug forms

2E Biopharmaceutics/Pharmacokinetics

  • 2E01 biological principles of dosage forms
  • 2E02 basic principles of in vivo drug kinetics (linear and nonlinear)
  • 2E03 principles of bioavailability/bioequivalence
  • 2E04 physiologic determinates of drug onset and duration
  • 2E05 drug, disease, and dietary influences on absorption, distribution, metabolism, and excretion
  • 2E06 the pharmacokinetic-pharmacodynamic interface

2F Pharmacogenomics

  • 2F01 genetic basis for disease and drug action
  • 2F02 genetic basis for alteration and drug metabolism
  • 2F03 genome and proteomic principles in relation to disease and drug development
  • 2F04 genetic basis for individualizing drug doses

2G Extemporaneous Compounding/Parenteral/Enteral

  • 2G01 United States Pharmacopeia guidance on compounding and FDA regulation of compounding
  • 2G02 techniques and principles used to prepare and dispense individual extemporaneous prescriptions including dating of compounded dosage forms
  • 2G03 extemporaneous liquid (parenteral, enteral), solid, semi-solid, and topical preparations
  • 2G04 dosage form preparation calculations
  • 2G05 sterile admixture techniques
    • a United States Pharmacopeia (USP) requirements for sterile compounding
    • b stability and sterility testing and dating
    • c clean room requirements
    • d infusion devices and catheters

Area 3 – Social/Behavioral/Administrative Sciences (22%)

3A Health Care and Public Health Delivery Systems

  • 3A01 introduction to United States, state, and local health care delivery systems and their interfaces and how they compare to those in other industrialized countries
  • 3A02 social, political, and economic factors influencing the delivery of health care (including financing and reimbursement mechanisms, health disparities, reform, etc)
  • 3A03 pharmacy and health care organizations (private and public insurers of third party administration, pharmaceutical industry, managed care organizations, PBMs, etc)
  • 3A04 health policy development and evaluation
  • 3A05 importance of involvement in pharmacy organizational, regulatory, state, and federal issues
  • 3A06 conflict between medical care and public health
  • 3A07 contributions of public health efforts to health status improvements (infectious disease control, chronic disease preventions, demographics, and social and physical environmental factors, etc)

3B Economics/Pharmacoeconomics

  • 3B01 use of pharmacoeconomic analyses (ie, cost-benefit analysis, cost-effectiveness analysis, cost-minimization analysis, cost-utility analysis)
  • 3B02 applications of economic, clinical, and humanistic outcomes to improve allocation of limited health care resources
  • 3B03 general macro and micro economic principles

3C Pharmacy Management

  • 3C01 management principles (planning, organizing, directing, and controlling pharmacy resources) applied to various pharmacy practice setting and patient outcomes
  • 3C02 personnel management – including leadership
  • 3C03 managing goods and services (marketing, purchasing/inventory management, and merchandising)
  • 3C04 financial accounting
  • 3C05 risk management in pharmacy practice

3D Pharmacoepidemiology

  • 3D01 application of epidemiological study designs to study drug use and outcomes in large populations
  • 3D02 data sources and analytic tools that provide an estimate of the probability of beneficial or adverse effects of medication use in large populations
  • 3D03 methods for continually monitoring unwanted effects and other safety-related aspects of medication use in large populations

3E Pharmacy Law and Regulatory Affairs

  • 3E01 administrative, civil, and criminal liability
  • 3E02 a pharmacist’s responsibilities and limits under the law
  • 3E03 the authority, responsibilities, and operation of agencies and entities that administer laws and regulations related to prescription, and over-the-counter medications

3F Biostatistics and Research Design

  • 3F01 commonly used experimental and observational study designs
  • 3F02 commonly used statistical tests and their appropriate application
  • 3F03 evaluation of statistical results including an understanding of statistical versus clinical significance

3G Ethics

  • 3G01 principles of biomedical ethics
  • 3G02 ethical dilemmas in the delivery of patient-centered care, including
  • a conflicts of interest
  • b end-of-life decision making
  • c development, promotion, sales, prescription, and use of drugs
  • d working in groups
  • 3G03 research ethics
  • 3G04 professional behavior (ie, professionalism, code of ethics, oath of the pharmacist)

3H Core Communication Concepts and Skills

  • 3H01 patient counseling skills including active listening and empathy
  • 3H02 assertiveness and problem-solving techniques, handling difficult situations – patients and other core providers
  • 3H03 interviewing techniques
  • 3H04 health literacy
  • 3H05 cultural competency

3I Social and Behavioral Aspects encountered in Practice

  • 3I01 health, illness, and sick role behaviors
  • 3I02 principles of behavior modification
  • 3I03 patient adherence
  • 3I04 caregiving throughout the life cycle
  • 3I05 death and dying
  • 3I06 patients’ and other health care providers’ perceptions of pharmacists’ capabilities

3J Medication Dispensing and Distribution Systems

  • 3J01 safe and effective preparation and dispensing of medications in all types of practice settings
  • 3J02 development and maintenance of patient medication profiles
  • 3J03 role of automation and technology
  • 3J04 continuous quality improvement programs or protocols in the medication-use process, including identification and prevention of medication errors and establishment of error reduction programs, technology of drug information retrieval for quality assurance

Area 4 – Clinical Sciences (32%)

4A Literature Evaluation – Practice Guidelines and Clinical Trials

  • 4A01 principles of clinical practice guidelines for various disease states and their interpretation in the clinical setting
  • 4A02 integration of core scientific and systems-based knowledge in patient care decisions
  • 4A03 reinforcement of basic science principles relative to drug treatment protocols and clinical practice guidelines
  • 4A04 evaluation of clinical trials that validate treatment usefulness

4B Drug Information

  • 4B01 fundamentals of the practice of drug information
  • 4B02 application of drug information skills for delivery of medication therapy management
  • 4B03 the ability to judge the reliability of various sources of information

4C Clinical Pathophysiology

  • 4C01 pathophysiology of disease states amenable to pharmacist intervention

4D Clinical Pharmacokinetics/Pharmacogenomics

  • 4D01 clinical pharmacokinetics/pharmacogenomics of commonly used and low-therapeutic-index drugs
  • 4D02 clinical basis for individualizing drug therapy

4E Clinical Prevention and Population Health

  • 4E01 promotion of wellness and nonpharmacologic therapies
  • 4E02 disease prevention and monitoring

4F Medication Therapy Management - Patient Assessment, Clinical Pharmacology, and Therapeutics

  • 4F01 concepts of pharmacist-provided patient care and medication therapy management services
  • 4F02 importance of and techniques for obtaining a comprehensive patient history
  • 4F03 patient assessment (eg, inspection, palpation, percussion, auscultation), terminology, and the modifications caused by common disease states and drug therapy
  • 4F04 common clinical laboratory values and diagnostic tests and their clinical role
  • 4F05 OTC point-of-care testing devices (eg, glucometers, pregnancy tests, home testing for HbA1c, drug screening).
  • 4F06 false positive and false negative results
  • 4F07 therapeutic drug concentrations and their interpretation
  • 4F08 problem identification (eg, duplication dosage, drug interactions, dietary interactions, adverse drug reactions and interactions, frequency dosage form, indication mismatches) and resolution planning
  • 4F09 triage and referral skills
  • 4F10 designing of patient-centered, culturally relevant treatment plans
  • 4F11 application of evidence-based decision making to patient care
  • 4F12 nonprescription and dietary supplements
  • 4F13 drug monitoring for positive and negative outcomes (including drug induced disease)
  • 4F14 clinical management of drug toxicity and overdosage